DiscoveRx Launches Assay for Beta-Arrestin Based Screening
Product News Apr 13, 2007
DiscoveRx has announced the release of the PathHunter™ Flash Detection Kit to enable ß-arrestin recruitment by a GPCR in 30 seconds, permitting screens of up to 1,000,000 compounds in 48 hours.
Unlike lengthy reporter gene assays, PathHunter ß-arrestin assays are direct and hence minimize the opportunity for off-target effects. A ligand-activated, GPCR-arrestin interaction combines two ß-galactosidase fragments, enabling rapid chemiluminescent detection in a homogeneous format. The kit is designed for whole class of plate readers with onboard fluidics and flash detection mode.
Additionally, screening campaigns can be accelerated by conducting ß-arrestin and calcium assays in the same well on same instrument, without need of cell fixation, when using instruments capable of real-time fluorescence and flash chemiluminescence.
With an expanding list of GPCR Beta-Arrestin assays (>90 assays) being added to its product offering, DiscoveRx has a solution for virtually any GPCR screening campaign.